We are live on ! Find out more
SYRE icon

Spyre Therapeutics
SYRE

129 hedge funds and large institutions have $953M invested in Spyre Therapeutics in 2025 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 64 increasing their positions, 25 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

156% more repeat investments, than reductions

Existing positions increased: 64 | Existing positions reduced: 25

74% more call options, than puts

Call options by funds: $1.05M | Put options by funds: $603K

50% more funds holding in top 10

Funds holding in top 10: 2 → 3 (+1)

2.49% more ownership

Funds ownership: 103.07% → 105.56% (+2.5%)

6% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 17

0% more funds holding

Funds holding: 129 → 129 (0)

5% less capital invested

Capital invested by funds: $1B → $953M (-$51.7M)

Holders
129
Holders Change
–
Holders Change %
0%
% of All Funds
1.7%
Holding in Top 10
3
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+50%
% of All Funds
0.04%
New
18
Increased
64
Reduced
25
Closed
17
Calls
$1.05M
Puts
$603K
Net Calls
+$446K
Net Calls Change
+$628K

Top Buyers

Rank Fund Capital Flow
1
TCM
Tang Capital Management
California
+$17M
2
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
+$10.1M
3
BBA
Baker Bros. Advisors
New York
+$9.27M
4
BlackRock
BlackRock
New York
+$6.43M
5
Morgan Stanley
Morgan Stanley
New York
+$4.97M

Top Sellers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
-$15.2M
2
PA
Perceptive Advisors
New York
-$11.6M
3
DCM
Driehaus Capital Management
Illinois
-$9.35M
4
PBA
Paradigm Biocapital Advisors
New York
-$3.8M
5
Adage Capital Partners
Adage Capital Partners
Massachusetts
-$2.86M
Name Holding Trade Value Shares
Change 		Change in
Stake
SS
126
SBI Securities
Japan
$165 +$89 +6 +120%
US Bancorp
127
US Bancorp
Minnesota
$150 +$15 +1 +11%
LFG
128
Larson Financial Group
Missouri
$90 -$562 -38 -86%
SC
129
Stempoint Capital
New York
– -$2.2M -136,139 Closed
Citadel Advisors
130
Citadel Advisors
Florida
– -$2.11M -130,884 Closed
SFM
131
Soros Fund Management
New York
– -$2.02M -125,000 Closed
EAM
132
EFG Asset Management
Oregon
– -$1.33M -82,472 Closed
PM
133
Prosight Management
Texas
– -$1.21M -74,921 Closed
WC
134
Wexford Capital
Florida
– -$618K -38,292 Closed
XT
135
XTX Topco
Cayman Islands
– -$460K -28,499 Closed
CF
136
Corebridge Financial
Texas
– -$316K -19,595 Closed
Natixis Advisors
137
Natixis Advisors
Massachusetts
– -$265K -16,401 Closed
ACM
138
Aquatic Capital Management
Illinois
– -$208K -12,903 Closed
SG Americas Securities
139
SG Americas Securities
New York
– -$115K -7,122 Closed
SSG
140
Summit Securities Group
New York
– -$2.15K -133 Closed
ACM
141
Aster Capital Management
United Arab Emirates
– -$2.48K -126 Closed
CA
142
CoreCap Advisors
Michigan
– -$662 -41 Closed
SC
143
Stephens Consulting
Michigan
– -$323 -20 Closed
PA
144
Parallel Advisors
California
– -$226 -14 Closed
Amundi
145
Amundi
France
– -$70 -5 Closed
C
146
Covestor
United Kingdom
– +$30 +2 +50%
2 3 4 5
6

SYRE Hedge Fund Activity: Q2 2025 in Review

129 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Spyre Therapeutics (SYRE) for Q2 2025, worth a combined $953M — down 5.1% from $1B a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new SYRE positions and 17 closed out — a net gain of 1 holder — while 64 added to existing stakes and 25 trimmed.

The largest buyer was Tang Capital Management, adding an estimated $17M. The largest seller was Janus Henderson Group, cutting an estimated $15.2M.

  • 129 institutional investors held Spyre Therapeutics (SYRE) as of Q2 2025, unchanged from Q1 2025.
  • Funds reported $953M of Spyre Therapeutics stock for Q2 2025, down 5.1% quarter-over-quarter.
  • 18 funds opened new Spyre Therapeutics positions in Q2 2025 and 17 closed out, a net change of +1 holder.
  • The largest Spyre Therapeutics buyer in Q2 2025 was Tang Capital Management, an estimated $17M added.
  • The largest Spyre Therapeutics seller in Q2 2025 was Janus Henderson Group, an estimated $15.2M sold.

Based on aggregated 13F filings for Q2 2025.